Understanding Real World Use of a protein tyrosine kinase inhibitor (TKI) in CML

You are here:

Background	Client keen to understand effectiveness, tolerability and safety of a protein tyrosine kinase inhibitor (TKI) in patients with CML used during routine clinical practice. Data collected to date was limited, but clinicians were keen to see further evidence in all aspects.
RWD Solution	An international, multi-centre, retrospective, non-interventional research study. Approval was gained from HRA, ethics, NIHR portfolio and local research and development departments. Following consent, data was collected from patient medical records, cleaned centrally and analysed by pH.
Outputs	Data demonstrated that the (TKI) observed is an effective and tolerable treatment in normal clinical practice The RW response data was consistent with clinical trial data already held Oral presentation of results at BSH 2017 by KOL Haematologica journal article under development